Clinical trials: Heart Failure New York Heart Association Class III
Heart Failure NYHA Class III
PRODIGY Registry in NYHA Class III Heart Failure Patients
This is an observational, prospective, single arm, multi-center registry to evaluate the Cordella™ Heart Failure System (CHFS) in up to 250 NYHA Class III HF patients .
- Trial name
- NCT03623165
- Testing
- Cordella™ Heart Failure System
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Endotronix, Inc.
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study.
- Trial name
- ALLEVIATE-HF (NCT04452149)
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention
- Where
- 53 sites in United States
- Volunteers
- 826 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Heart Failure NYHA Class III
HEart fAiluRe evaluaTion Questionnaire
The "four-point" questionnaire by Severo and his associates was weighted in 2011 in the Portuguese population and aims to characterize the severity of the symptoms of heart failure by providing a way to minimize the reliability…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class II, Heart Failure NYHA Class I
- Trial name
- HEART (NCT03895073)
- Testing
- healthy volunteers
- Where
- Greece
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- John Parissis
Heart Failure, Heart Failure NYHA Class II
Heart Failure Management for Patient With CIED Remotely Monitored
This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- PROACT-HF (NCT07247032)
- Testing
- SmartSignalHF, HF RM standard of care
- Where
- France
- Volunteers
- 1,132 people
- Sponsor
- Implicity
Heart Failure, Heart Failure NYHA Class I
Promoting Well-being and Health in Heart Failure
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24…
- Conditions
- Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT04829617
- Testing
- PP-MI Intervention, MI-alone Intervention
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Massachusetts General Hospital
Decompensated Chronic Heart Failure, Heart Failure NYHA Class III
Epidemiology and Prognostic of the Acute Heart Failure
EPICAL 2 (Epidemiology and prognostic of the Acute Heart Failure) is an epidemiological, observational, prospective and multicenter study.
- Conditions
- Decompensated Chronic Heart Failure, Heart Failure NYHA Class III, Acute Pulmonary Edema, Cardiogenic Shock
- Trial name
- EPICAL2 (NCT02880358)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Central Hospital, Nancy, France
Congestive Heart Failure
Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers.
- Trial name
- NCT00063687
- Testing
- Oxypurinol
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Advanz Pharma
NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C
The objective of this investigation is to evaluate the safety and effectiveness of the OPTIMIZER® System in subjects with medically refractory moderate-to-severe heart failure.
- Trial name
- FIX-HF-5C (NCT01381172)
- Testing
- Optimizer System, No intervention: Optimal medical therapy
- Where
- 42 sites in United States, Czechia and 1 more
- Volunteers
- 160 people
- Sponsor
- Impulse Dynamics
NYHA Class III Heart Failure
Bioimpedance Spectroscopy Compared to CardioMEMS™
Comparison of changes in diastolic pulmonary artery pressure as measured by CardioMEMS™ to impedance parameters as measured by ImpediMed's BIS technology.
- Trial name
- NCT02857231
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ImpediMed Limited
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Remission From Stage D Heart Failure
The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery…
- Trial name
- RESTAGE-HF (NCT01774656)
- Testing
- Pharmacological Treatment
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Louisville
Diabetes, Heart Failure
Multipolar CRT-d and Diabetes
Background: Type 2 Diabetes Mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart (HF) patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d).
- Conditions
- Diabetes, Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT03095196
- Testing
- Multipolar CRT-d, plus conventional drug therapy for HF., Bipolar CRT-d, plus conventional drug therapy for HF., HF drugs
- Volunteers
- 190 people
- Sponsor
- Celestino Sardu
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CardioMEMS HF System Real-World Evidence Post-Approval Study
The purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.
- Trial name
- NCT06306573
- Testing
- CardioMEMS HF System
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Abbott Medical Devices
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
- Trial name
- NCT07864558
- Testing
- Individualized myPACE pacemaker programming
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tufts Medical Center
Heart Failure
TRI-V Heart Failure (HF) Implanted Cardioverter Defibrillator (ICD) Study
It's the aim of this study to investigate the impact of Right Ventricular (RV) lead position (RV-apex, His bundle area, RV-apex+His bundle area) in combination with individually optimized Left Ventricular (LV) lead placement and…
- Trial name
- TRI-V (NCT00746135)
- Testing
- Device Implantation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Effects of a Walking Program and Inspiratory Muscle Training in Individuals With Chronic Heart Failure
Individuals with chronic heart failure need a "safe and effective" exercise program that could enhance their quality of life. In this study, we examined whether an experimental exercise program of autonomous walking and…
- Trial name
- NCT01560871
- Testing
- High-intensity IMT plus walking, Low-intensity IMT plus walking
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Texas Woman's University
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study)
Chronic heart failure (CHF) is a major and growing public health problem and poses economic burden on the society. There is a need for a safe, equipment-free, low-cost, and easily implemented exercise-based cardiac rehabilitation…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Trial name
- BESMILE-HF (NCT03180320)
- Testing
- BESMILE-HF program, Usual medications
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Sustaining Home Heart Failure Palliative Care in Rural Appalachia
The aim of this mixed methods randomized controlled trial is to test the integrated nurse-led intervention bundle for family home care management of end-stage heart failure and palliative care in rural Appalachia.
- Trial name
- NCT06791850
- Testing
- HF-FamPALhomeCARE
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- West Virginia University
Heart Failure
Warfarin and Antiplatelet Therapy in Chronic Heart Failure
Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics.
- Trial name
- NCT00007683
- Testing
- Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
- Where
- 134 sites in United States, Canada and 1 more
- Volunteers
- 1,587 people
- Sponsor
- US Department of Veterans Affairs
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients
ADLIFE is a EU-funded project developing innovative digital health solutions to support healthcare planning and care delivery for patients with advanced chronic conditions (chronic obstructive pulmonary disease and/or heart…
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Chronic Obstructive Pulmonary Disease Severe
- Trial name
- ADLIFE (NCT05575336)
- Testing
- ADLIFE intervention
- Where
- 7 sites in Denmark, Germany and 3 more
- Volunteers
- 185 people
- Sponsor
- Biosistemak Institute for Health Systems Research
Heart Failure NYHA Class III
SIRONA 2 Trial Heart Failure NYHA Class III
This is a prospective, multi-center, open-label, single-arm CE-Mark trial to assess device safety and efficacy of the Cordella PA Sensor System in up to 75 New York Heart Association (NYHA) Class III Heart Failure patients who…
- Trial name
- NCT04012944
- Testing
- Cordella™ Pulmonary Artery Sensor System
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 81 people
- Sponsor
- Endotronix, Inc.